EE170 A Cost-Effectiveness Analysis, with Public Healthcare Payers’ Perspective, of Oral Semaglutide Versus Luseogliflozin Hydrate for Patients with Type 2 Diabetes Mellitus in a Japanese Clinical Setting

Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.439
https://www.valueinhealthjournal.com/article/S1098-3015(23)03569-6/fulltext
Section Title :
Section Order : 12465
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03569-6&doi=10.1016/j.jval.2023.09.439
HEOR Topics :
Tags :
Regions :